Ruximonab 500 mg Injection 50 ml is classified as a monoclonal antibody medication used for treating non-Hodgkin’s lymphoma and chronic lymphocytic leukaemia. Additionally, it is utilized in the management of rheumatoid arthritis when combined with methotrexate, as well as granulomatosis in conjunction with glucocorticoids. This injection is also effective for treating Pemphigus Vulgaris (PV) and mature B-cell acute leukaemia (B-AL).
The active ingredient in Ruximonab 500 mg Injection 50 ml is Rituximab, which functions by blocking the transcription of DNA and RNA necessary for the proliferation of cancer cells. This action helps to inhibit the growth and dissemination of both cancerous and non-cancerous cells. Furthermore, Ruximonab 500 mg Injection 50 ml interferes with the immune response that leads to inflammation in joint tissues, thereby alleviating pain and inflammation while preventing joint damage and the progression of disease over time.
Potential side effects of Ruximonab 500 mg Injection 50 ml include pale skin, painful urination, night sweats, flushing, back pain, nausea, vomiting, diarrhea, abdominal pain, mouth sores, skin peeling, reactions at the injection site, and discomfort at the injection location. These side effects typically do not necessitate medical intervention and tend to resolve on their own. However, if they persist or worsen, it is advisable to consult a healthcare professional. Ruximonab 500 mg Injection 50 ml is administered parenterally by a qualified healthcare provider, so self-administration is not recommended.
Avoid using Ruximonab 500 mg Injection 50 ml if you have a known allergy to it or any of its components. It is important to inform your doctor of your complete medical history, including any current medications, to avoid potential side effects or interactions. Additionally, notify your doctor if you have liver or kidney disease, a hepatitis B virus infection, heart conditions, any active infections, or gastrointestinal disorders prior to receiving this injection. Ruximonab 500 mg Injection 50 ml may lead to bowel obstruction and perforation, reactivation of Hepatitis B infection, and cardiac issues.
